Insilico hits highest since debut on FDA IND approval for Parkinson's treatment

Insilico Medicine Cayman TopCo

23/01/2026 03:21

** Shares of Insilico Medicine Cayman TopCo 3696.HK surge 9.3%, in the fourth straight session of gains, to HK$64.4, their highest level since debuting in Hong Kong on December 30

** Since its debut, the stock is up 84%

** The biotechnology group says ISM8969, its orally available NLRP3 inhibitor intended for the treatment of Parkinson's Disease, has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA)

** ISM8969 achieves desirable blood-brain barrier penetration, an advantage that enables it to cross the natural protective barrier between the central nervous system and the bloodstream, holding great promise for treating neuroinflammation-related diseases

** YTD, stock is up 71.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))